Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Core Insights - Ocular Therapeutix will host a webcast on February 17, 2026, to review topline results from the SOL-1 Phase 3 clinical trial of AXPAXLI™ for wet age-related macular degeneration [1] - Detailed data from the trial will be presented at the 49 Macula Society Annual Meeting from February 25 to 28, 2026 [1] Company Overview - Ocular Therapeutix, Inc. is an integrated biopharmaceutical company focused on redefining the retina experience [3] - AXPAXLI™ (OTX-TKI) is an investigational product candidate for retinal diseases, currently in Phase 3 trials for wet AMD and diabetic retinal disease [3] - The company utilizes its proprietary ELUTYX™ technology in its commercial product DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain [4] Product Pipeline - DEXTENZA is approved for treating ocular inflammation and pain post-surgery and allergic conjunctivitis in patients aged two years or older [4] - Ocular is also developing OTX-TIC, a travoprost intracamreal hydrogel that has completed Phase 2 trials for open-angle glaucoma or ocular hypertension [4]